EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Considerations for establishing occupational exposure limits for small molecule kinase inhibitors in drug development

Tyler Nicholas, Eric Morinello, Chandrika Moudgal, Alexandre Beaulieu, Jessica Graham

Frontiers in Toxicology · 26.03.2026 · 8

DOI: 10.3389/ftox.2026.1743558 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Toxicology, online erschienen am 26.03.2026. Verfasst von Tyler Nicholas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., Development Sciences, Translational Safety, South San Francisco, CA, United States. Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Protein kinases regulate various cell cycle functions, and small molecule kinase inhibitors (SMKIs) represent a growing class of therapeutics. In the pharmaceutical industry, occupational toxicologists enable research and development (R&D) and manufacturing activities for SMKIs by deriving health-based exposure limits (HBELs), including occupational exposure limits (OELs) and occupational exposure bands (OEBs), often in data-limited R&D settings.

Methods

The objective of this study was to evaluate health hazard data for FDA-approved SMKIs and apply a quantitative framework to estimate OELs and map them to OEBs to guide occupational health and safety practices. We compiled health hazard data for SMKIs (n = 86) from literature sources and drug labels including data on genotoxicity, carcinogenicity, developmental and reproductive toxicity (DART), minimum daily therapeutic dose, and sensitive subpopulations. For orally administered SMKIs (n = 83), we estimated OELs using a standardized dose-based approach that incorporates adjustment factors and bioavailability. Estimated OELs were then mapped to OEBs and evaluated by target family.

Results

Estimated OELs ranged from 0.05 to 96 µg/m 3 , with 82% falling between 1 and <100 µg/ 3 , spanning OEB 2 and OEB 3A. Developmental toxicity was regarded a class effect, while genotoxicity and carcinogenicity were less frequent and varied by target family.

Discussion

Several target families, including JAK, FGFR, MEK, mTOR, PI3K, and VEGFR inhibitors, exhibited lower estimated OELs and may warrant more protective OEBs in data-limited R&D settings. This analysis demonstrates that a default OEB of 1 to <10 µg/m 3 (3A) is likely protective for most SMKIs. These findings provide a quantitative, mechanism-informed framework to guide occupational risk management for SMKIs.

Schlagwörter

Stichwörter der Autor:innen

health hazard datahealth-based exposure limitoccupational exposure bandoccupational exposure limitrisk assessmentsmall molecule kinase inhibitor

Autor:innen und Institutionen

  • Genentech, Inc., Development Sciences, Translational Safety, South San Francisco, CA, United States.

Zitieren

APA

Nicholas, T., Morinello, E., Moudgal, C., Beaulieu, A., & Graham, J. (2026). Considerations for establishing occupational exposure limits for small molecule kinase inhibitors in drug development. Frontiers in Toxicology, 8. https://doi.org/10.3389/ftox.2026.1743558

Vancouver

Nicholas T, Morinello E, Moudgal C, Beaulieu A, Graham J. Considerations for establishing occupational exposure limits for small molecule kinase inhibitors in drug development. Frontiers in Toxicology. 2026;8. doi:10.3389/ftox.2026.1743558

BibTeX
@article{Nicholas2026,
  author = {Nicholas, Tyler and Morinello, Eric and Moudgal, Chandrika and Beaulieu, Alexandre and Graham, Jessica},
  title = {Considerations for establishing occupational exposure limits for small molecule kinase inhibitors in drug development},
  journal = {Frontiers in Toxicology},
  year = {2026},
  volume = {8},
  doi = {10.3389/ftox.2026.1743558}
}
Kostenlos starten →